Agenus appoints Ulf Wiinberg to board of directors
Mr. Wiinberg has more than 30 years of pharmaceutical experience and currently serves on the boards of multiple global drug development companies.
Mr. Wiinberg joins the board as an independent director with almost 20 years of senior leadership experience, most recently serving as Chief Executive Officer of H. Lundbeck A/S, a global pharmaceutical company developing and marketing treatments for psychiatric and neurological disorders.
He previously served on the boards of several healthcare industry associations and held multiple executive roles at Wyeth, one of the world’s largest research-driven pharmaceutical companies that was acquired by Pfizer in 2009.
He served as President of Wyeth Europe, Africa and Middle East; President of Consumer Healthcare; Managing Director of Wyeth UK, and in various commercial positions.
Mr. Wiinberg currently serves on the boards of UCB SA, a global biopharmaceutical company based in Belgium, Avillion LLP (Chairman), a London-based drug development company, Hansa Medical AB (Chairman), a Swedish biopharmaceutical company, Alfa Laval AB, a Swedish industrial company, and Nestle Health Science. ■
LATEST MOVES FROM Massachusetts
- Pegasystems appoints Matt Cushing as vice president
- Akcea Therapeutics appoints three to board
- Silicon Therapeutics appoints Woody Sherman as CSO
- Dunkin' Brands Group CFO Paul Carbone to leave
- Abpro appoints Gavin MacBeath as CSO
More inside POST
Nordstrom Q4 EPS $1.15 Earnings